drugset / Trial / NCT03312894

Efficacy and Safety of TAK-653 in Treatment-Resistant Depression

NCT03312894

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of TAK-653 compared with placebo in maintaining the effect of ketamine treatment on depressive symptoms.

Timeline

Start
2018-02-15
Primary completion
2019-02-28
Completion
2019-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject OSAVAMPATOR Small molecule 6 mg Oral

Indications

No indication recorded.